ACTRN12619000878178.

Study name	A randomised controlled trial of venlafaxine to treat patients with knee osteoarthritis pain
Methods	Double‐blind, parallel‐arm, placebo‐controlled, 2‐arm RCT
Participants	Age 40‐80 years Knee pain for ≥ 14 days of each month for > 3 months Significant knee pain on most days (defined as a VAS > 40 mm) on 100 mm VAS pain Meet ACR clinical criteria for knee OA confirmed by a rheumatologist
Interventions	Venlafaxine; 75 mg daily for 4 weeks and then increase to 150 mg daily for next 8 weeks Placebo
Outcomes	Pain intensity Physical function Quality of life painDETECT score Anxiety Pain catastrophising Pain disability Depression Responders (using OMERACT‐OARSI criteria)
Starting date	20 June 2019
Contact information	Dr Feng Pan Menzies Institute for Medical Research 17 Liverpool Street Hobart Tasmania 7000 Australia Feng.Pan@utas.edu.au
Notes